ライフサイエンスコーパス: ascites

1 0.809 (if female) x 0.92 (if moderate/severe ascites).

2 0.809 (if female) x 0.92 (if moderate/severe ascites).

3 ass C cirrhosis, hyponatremia, or refractory ascites.

4 als of satavaptan in cirrhosis patients with ascites.

5 of control rats and rats with cirrhosis and ascites.

6 tient, on dialysis, were ventilated, or with ascites.

7 ng to a technique validated in patients with ascites.

8 follow-up evaluation, mainly for refractory ascites.

9 ization and leakiness culminating in massive ascites.

10 ase progression, tumor burden, and volume of ascites.

11 es of patients with cirrhosis and refractory ascites.

12 d be useful in the differential diagnosis of ascites.

13 ites analyses in the diagnosis of HF-related ascites.

14 of age; 208 (40%) of the children presented ascites.

15 r cirrhosis, the second-most common cause of ascites.

16 at is, it was the best to rule in HF-related ascites.

17 0.0) and was the best to rule out HF-related ascites.

18 es normalized with concomitant resolution of ascites.

19 varices, portal hypertensive gastropathy, or ascites.

20 contractility in experimental cirrhosis with ascites.

21 mice, with subsequent development of chylous ascites.

22 90-day mortality of cirrhotic patients with ascites.

23 on the mortality of cirrhotic patients with ascites.

24 ort an unidentified growth factor present in ascites.

25 ards of care for patients with cirrhosis and ascites.

26 tion other than sepsis, such as bleeding and ascites.

27 ting albumin infusion in patients with tense ascites.

28 to treat HRS in patients with cirrhosis and ascites.

29 boptimal for patients with cirrhosis-related ascites.

30 etically silenced in cell lines derived from ascites.

31 cant part of the cell-stimulating effects of ascites.

32 oxicity in the presence of immunosuppressive ascites.

33 the gallbladder wall, pleural effusion, and ascites.

34 al mortality in culture negative neutrocytic ascites.

35 increased RNA abundance when grown in human ascites.

36 associated with reduced risk of bleeding and ascites.

37 th diagnosis of culture negative neutrocytic ascites.

38 associated with culture negativeneutrocytic ascites.

39 es of patients with cirrhosis and refractory ascites.

40 ffect (FE 204038) in rats with cirrhosis and ascites.

41 ll populations into primary tumors and their ascites.

42 c, avascular tumors typical of patients with ascites.

43 an increase in IL10 levels in both serum and ascites.

44 ncrease mortality in cirrhosis patients with ascites.

45 edictors for ELF in patients with refractory ascites.

46 of HE or SBP in patients with cirrhosis with ascites.

47 Of the total 4,576 cirrhotic patients with ascites, 1,294 (28.2%) were diagnosed with infectious di

48 e of patients in either treatment group were ascites (13 [5%] of 277 patients treated with ramuciruma

49 was 15, serum albumin was 3.0 g/dL, 28% had ascites, 18% had hepatic encephalopathy, and 83% were Ch

50 Of the 1120 cirrhosis patients with ascites, 21 (1.9 %) were diagnosed with epilepsy.

51 inal pain (in 18% of patients), nausea (8%), ascites (3%), fatigue (3%), gastric stenosis (3%), hepat

52 Grade 3 or higher adverse events included ascites (34 [8%] in the placebo group vs 52 [11%] in the

53 frequent indication for TIPS was refractory ascites (50 of 54; 93%).

54 in the subgroup of patients with refractory ascites (588 patients, adjusted hazard ratio = 1.02, 95%

55 substudy, EIVPD was higher in patients with ascites (6.5 [5.4-8.5] versus 4.0 [3.9-5.1] mm Hg, P = 0

56 33.9%, P = 0.004) and refractory hydrothorax/ascites (6.9% vs. 16.5%, P = 0.019) in the experimental

57 Such mice began to develop malignant ascites about 6 months after injection, which was due to

58 st to these groups, MSC1-therapy led to less ascites accumulation, increased CD45+leukocytes, decreas

59 All patients had measurements of serum-ascites albumin gradient (SAAG), total protein concentra

60 ing immune cells, as found in ovarian cancer ascites, AMG655-induced apoptosis was not enabled to any

61 Serum BNP is more accurate than ascites analyses in the diagnosis of HF-related ascites.

62 splenomegaly (52/67), fever (33/64), oedema, ascites, anasarca, or a combination (29/37), elevated so

63 nomegaly with multiple granulomas as well as ascites and a left-sided pleural effusion.

64 histopathology, culminating in haemorrhagic ascites and a median survival period of 7.5 weeks.

65 Her physical examination revealed tense ascites and abdominal collateral veins.

66 ver, mice treated with mP-PTX had no obvious ascites and body-weight loss.

67 es the need for subjective variables such as ascites and encephalopathy, a requirement in the convent

68 in levels, as well as presence or absence of ascites and encephalopathy.

69 al normalized ratio at waitlisting, and less ascites and encephalopathy.

70 Pelvic ultrasound revealed abundant ascites and enlarged ovaries, at 8 cm average diameter.

71 Ascites and hepatic encephalopathy was documented in 26%

72 able overall lower probability of developing ascites and HRS.

73 recorded ex vivo in rats with cirrhosis and ascites and in control rats after the injection in the c

74 in 16 of 95 (16.8%) patients with refractory ascites and in four of 121 (3.3%) patients with other in

75 LVDD was more frequent in patients with ascites and increased PRA than patients without ascites

76 ize throughout the abdominal cavity, causing ascites and killing 100% of the mice by 13 mo.

77 h significantly increased stromal expansion, ascites and metastases.

78 eloped liver insufficiency manifested by new ascites and peripheral edema, treated with diuretics, a

79 hild class A [69.4% sessions (n = 77)] or B; ascites and portal vein invasion was present in 18 (16.2

80 also other PH-related complications, such as ascites and portosystemic encephalopathy.

81 nction had recovered, with resolution of her ascites and PS of 2.

82 The presence of ascites and serum sodium levels are important variables

83 raft models, high levels of soluble VEGFC in ascites and serum were detected, in association with dis

84 ovarian cancer cells collected from patient ascites and solid tumors, and established cell lines bef

85 Ascites and splenomegaly were independent predictors for

86 the action of diuretics in the treatment of ascites and the ability of the plasma-ascitic albumin gr

87 s; one treated with 1.00 mg mAb/kg developed ascites and was euthanized 136 d after HCT.

88 This fetus developed ascites and was euthanized after 4 days.

89 rapeutic targets-ranging between 0 (thyroid, ascites) and 8.48 months (breast cancers)-and were somet

90 had whole body edema, thoracic and abdominal ascites, and bloody stools.

91 C, mice developed peritoneal carcinomatosis, ascites, and distant metastases.

92 Adult patients with cirrhosis, ascites, and HRS-1 (based on the 2007 International Club

93 uids such as amniotic fluid, liver cirrhosis ascites, and malignant ascites of ovarian cancer patient

94 nchorage-free growth in peritoneal fluid and ascites, and to colonize remote sites, are poorly define

95 y mass index, liver iron deposition, massive ascites, and use of 3.0 T were significantly associated

96 ase (REILD) has been defined as jaundice and ascites appearing 1 to 2 months after RE in the absence

97 Cirrhotic patients with ascites are prone to develop various infectious diseases

98 BACKGROUND & AIMS: Ascites are the most common complication of cirrhosis.

99 Presence of a severe associated disorder and ascites as a presenting symptom were associated with poo

100 Serum creatinine (P = 0.005), ascites as indication for TIPS (P = 0.04), and the prese

101 lestatic HCV at 6 months posttransplant with ascites, AST 503 IU/mL, alkaline phosphatase of 298 IU/m

102 ates with the absence of further bleeding or ascites at follow-up examinations of patients with cirrh

103 ted with stage, preoperative CA125 level and ascites at surgery.

104 e 4.6 and 4.3 in the patient with refractory ascites at the two post-TIPS time points, respectively.

105 his communication presents an explanation of ascites based solely on pathophysiological alterations w

106 ents with portal hypertension and refractory ascites before and 2 and 12 weeks after TIPS placement b

107 Ascites beyond the cul-de-sac was the single best indica

108 Ascites beyond the cul-de-sac, irrespective of attenuati

109 toneal fluid (subcapsular vs extracapsular), ascites beyond the cul-de-sac, peritoneal implants, ipsi

110 f Anesthesiologists) class >1, hypertension, ascites, bleeding disorders, systemic steroids, and lapa

111 n concentration in ascitic fluid, serum, and ascites BNP.

112 nd promotes macrophage proliferation in mice ascites, both of which improve innate immunity.

113 rified GD3, as well as substances within the ascites, bound to the CD1d antigenic-binding site and di

114 ed PRA than patients without ascites or with ascites but normal PRA.

115 ng (eg, alpha = .78 for pleural effusion and ascites) but was lower for others (eg, alpha = .08 for i

116 l of hvKP1Deltapeg-344 was observed in human ascites, but resistance to the bactericidal activity of

117 icient to proteins and reduced the volume of ascites by over 50%.

118 ma tumors, secondary omental metastases, and ascites cells isolated from serous ovarian cancer patien

119 were examined from patient derived malignant ascites cells.

120 ities associated with failure to rescue were ascites, chronic obstructive pulmonary disease, and diab

121 In experimental cirrhosis with ascites, continuous pressure of gut bacteria shapes the

122 a from three 1-year trials of satavaptan for ascites control.

123 The workup of patients with new onset ascites could be streamlined by obtaining serum BNP as a

124 inotropic effect in rats with cirrhosis and ascites counteracting the negative effects of oxidative

125 S-1 (based on the 2007 International Club of Ascites criteria of rapidly deteriorating renal function

126 Hemorrhagic ascites, defined as an ascitic fluid red blood cell (RBC

127 mor-bearing mice suppressed tumor growth and ascites development, significantly prolonging lifespan.

128 ncluded: fatty or cryptogenic liver disease, ascites, diabetes mellitus, and obesity.

129 Ascites drainage led to a reduction of TP53MAF concentra

130 pleural effusion and assisting its drainage, ascites drainage, ruling-in pneumothorax, central venous

131 34 patients were analysed; 19 had ascites due to cirrhosis and 15 from malignancy.

132 Treatment of mice with malignant ascites due to mesothelioma with rapamycin led to a mark

133 lity were older age, smoking, liver disease, ascites, emergency or semiurgent repair, and need for in

134 endpoints defined as hepatic decompensation (ascites, encephalopathy, and variceal bleeding), hepatoc

135 e of opioids, ribavirin use, the presence of ascites, encephalopathy, insomnia, and depression.

136 tion), and cirrhosis-specific complications (ascites, encephalopathy, spontaneous bacterial peritonit

137 ss who undergo TIPS placement for refractory ascites (especially in patients with MELD of 11 or 12) a

138 with rapamycin led to a marked reduction in ascites, extended survival and a 95-99% reduction in the

139 d multicellular aggregates (MCAs) present in ascites fluid adhere to the peritoneum and induce retrac

140 e demonstrate that the macrophage content in ascites fluid from human patients and the ID8 model dire

141 osuppressive cytokines were also elevated in ascites fluid of patients with tumors that highly expres

142 rvival of matrix-detached cells in a complex ascites fluid phase and subsequent adhesion to the mesot

143 strains in iron-poor minimal medium or human ascites fluid showed a significant and distinguishing 6-

144 Co-incubation of ovarian cancer cells with ascites fluid significantly increased sN4 shedding, whic

145 In human ascites fluid supplemented with exogenous siderophores,

146 patients, we detected 2-20-fold more sN4 in ascites fluid than serum.

147 gnificantly less than that of hvKP1 in human ascites fluid, and the survival of outbred CD1 mice chal

148 inants including CHO cell conditioned media, ascites fluid, DNA, and other antibodies with yields >85

149 heir wild-type parent hvKP1 ex vivo in human ascites fluid, human serum, and human urine and in vivo

150 hanced the growth/survival of hvKP1 in human ascites fluid.

151 ture supernatant, hybridoma media, and mouse ascites fluid.

152 08 and included 1198 cirrhosis patients with ascites followed for 1 year.

153 r growth, stroma formation, EMT, metastasis, ascites formation, and Wnt7b expression, and markedly pr

154 rubinemia, coagulopathy, encephalopathy, and ascites formation.

155 Large or refractory ascites frequently necessitates paracentesis.

156 novel therapeutic peptide, serous malignant ascites from highly resistant recurrent ovarian cancer p

157 the test that best discriminated HF-related ascites from other causes of ascites was serum BNP.

158 pancreatitis, hepatic failure/cirrhosis with ascites, gastrointestinal bleeding, or postlaparotomy.

159 Patients with culture negative neutrocytic ascites have a mortality rate comparable to spontaneous

160 Although the factors involved in cirrhotic ascites have been studied for a century, a number of obs

161 e volume paracentesis (LVP) in patients with ascites have never before been examined.

162 Patients and rats with cirrhosis and ascites have portal hypertension and circulatory dysfunc

163 of recurrent or de novo variceal bleeding or ascites (hazard ratio, 0.11; 95% confidence interval, 0.

164 r disease was defined by the development of: ascites, hepatic encephalopathy, variceal bleeding, prot

165 ll bladder wall thickness, pleural effusion, ascites, hepatomegaly, and splenomegaly are highly sugge

166 plications including hepatic encephalopathy, ascites, hepatorenal syndrome (HRS), and esophageal vari

167 ue to complications [hepatic encephalopathy, ascites, hepatorenal syndrome (HRS), and esophageal vari

168 n ovarian cancer cells isolated from patient ascites, HO-3867 inhibited cell migration/invasion and s

169 dence interval [CI] = 0.33-0.90; P = 0.018), ascites (HR = 1.81; 95% CI = 1.21-2.71; P = 0.004), and

170 associated with culture negativeneutrocytic ascites in a larger sample population.

171 e ability to perform longitudinal testing of ascites in a point-of-care setting could significantly i

172 xcretion and reduces portal hypertension and ascites in experimental cirrhosis.

173 peritoneal tumors and induce accumulation of ascites in mice.

174 nt related], and treatment-related worsening ascites in one patient) and three with relapsed or refra

175 oneal therapy for the treatment of malignant ascites in patients with EpCAM-positive carcinomas.

176 e of serum sodium levels and the presence of ascites in the pediatric setting remain to be clarified.

177 produced widely distributed solid tumors and ascites in the peritoneal cavity in 100% of animals.

178 ment-mediated bactericidal activity in human ascites in the presence and absence of opsonization.

179 tional cohort of patients with cirrhosis and ascites in their last year of life.

180 virus (YAV) is an aquabirnavirus that causes ascites in yellowtail, a fish often used in sushi.

181 ce died at 15-18 days after hepatectomy with ascites, increased plasma ammonia, and very small livers

182 the CatmAb on the major subsets of malignant ascites-infiltrating leukocytes and the molecular finger

183 Massive ascites, iron deposition, and high body mass index were

184 Malignant ascites is a common complication in the late stages of e

185 ype 1 (HRS-1) in patients with cirrhosis and ascites is a functional, potentially reversible, form of

186 Malignant ascites is a known consequence of vascular dysfunction,

187 Ascites is a major and common complication of liver cirr

188 Culture negative neutrocytic ascites is a variant of spontaneous bacterial peritoniti

189 Cirrhosis with ascites is associated with a high rate of gut bacterial

190 Escape of intestinal bacteria into the ascites is involved in the pathogenesis of spontaneous b

191 Ascites is the most common complication of cirrhosis and

192 is, particularly in cases where the cause of ascites is uncertain and/or could be the result of HF.

193 (LPA), a major tumor-promoting factor in EOC ascites, is an enzymatic product of autotaxin (ATX) and

194 The blood-isolated BJAB07104 and ascites-isolated BJAB0868 exhibit high similarity on the

195 Ascites, liver disease, diabetes, obesity, and primary s

196 elihood of cirrhosis, though the presence of ascites (LR, 7.2; 95% CI, 2.9-12), a platelet count <160

197 , presence and size of pleural effusions and ascites, lymphadenopathy, and distant metastases.

198 econdary lymphedema, chylothorax and chylous ascites, lymphatic malformations, and overgrowth syndrom

199 Patients with HCC often have ascites, making it a challenge to determine body mass in

200 nown about the extent to which patients with ascites meet these standards.

201 nt variceal bleeding (n = 25) and refractory ascites (n = 16).

202 metastases, malignant pleural effusion, and ascites obtained during disease progression, were analyz

203 into liver in the autopsy cases and into the ascites of 12 volunteers with liver cirrhosis was also s

204 ithelial and two mesenchymal cell lines from ascites of a bladder cancer patient (i.e. cells already

205 of PD-1(bright) NK cells were higher in the ascites of a cohort of patients with ovarian carcinoma,

206 afe and effective means to control malignant ascites of EOC.

207 luid, liver cirrhosis ascites, and malignant ascites of ovarian cancer patients.

208 Using cells isolated from the malignant ascites of patients with advanced ovarian cancer, we sho

209 Soluble VEGFC was detected in the plasma and ascites of patients with ovarian carcinoma, and VEGFR3 e

210 alignant epithelial cells harvested from the ascites of women with ovarian cancer, we show that tumor

211 the interstitium (edema) and the peritoneum (ascites) of nephrotic patients is classically thought to

212 no stigmata of chronic liver disease, and no ascites or encephalopathy or other associated clinical s

213 defined as presence of esophageal varices or ascites or low platelet count and splenomegaly.

214 ecrease the ex vivo growth/survival in human ascites or serum or decrease virulence in the in vivo in

215 Primary ovarian cancer cells from patient ascites or solid tumors sorted for alpha2-6 sialylation

216 ites and increased PRA than patients without ascites or with ascites but normal PRA.

217 varices (odds ratio [OR] = 3.27; P < 0.001), ascites (OR = 3.93; P < 0.001) and mortality (hazard rat

218 (hepatic encephalopathy, esophageal varices, ascites, or portal hypertension) or liver transplant wer

219 al symptoms, bilirubin, ulcer, pancreatitis, ascites, or radioembolization-induced liver disease occu

220 Marked ascites out of proportion to peripheral edema usually de

221 On univariate analysis, ascites (P = .02), liver disease (P = .02), diabetes (P

222 s (P = 0.03, HR = 0.96, 95% CI = 0.92-0.99), ascites (P = 0.001, HR = 2.59, 95% CI = 1.44-4.64), and

223 Female gender (p = 0.029, OR = 1.412), ascites (p = 0.030, OR = 1.212), elevated serum bilirubi

224 e diabetes was independently associated with ascites (P=0.05), bacterial infections (P=0.001), and en

225 independently associated with development of ascites (P=0.057), renal dysfunction (P=0.004), bacteria

226 ients with paracentesis after diagnosis with ascites, patients that received antibiotics for gastroin

227 tient-derived ovarian cancer xenografts from ascites (PDXa).

228 Algorithms that included diagnosis codes for ascites (PPV 75%; 95% CI 63-86%), cirrhosis (PPV 60%; 47

229 tive of Child-Pugh stage and the presence of ascites prior the second TACE.

230 came normalized and sera from GW2580-treated ascites protected against endothelial permeability.

231 s of patients with cirrhosis with refractory ascites (RA).

232 uid samples from 258 patients with malignant ascites randomized to catumaxomab or control groups to i

233 latory flow, thus reducing sodium retention, ascites recurrence, and variceal bleeding.

234 Chylous ascites refers to the accumulation of lipid-rich lymph i

235 Median amount of ascites removed was 5.99 L (IQR, 3.33-7.68 L).

236 isoforms were independently associated with ascites, renal impairment, and bacterial infection.

237 Ascites resolved in six of seven patients.

238 We enrolled 218 consecutive patients with ascites resulting from HF (n = 44), cirrhosis (n = 162),

239 hemodynamics in patients with cirrhosis and ascites; rifaximin did not affect glomerular filtration

240 y detecting both FR+ cells and free FR in an ascites sample obtained from an ovarian cancer patient.

241 Using nPLEX to analyze ascites samples from ovarian cancer patients, we find th

242 Of the ascites samples from the volunteers with liver cirrhosis

243 Patients with malignant ascites secondary to primary carcinomas benefit from int

244 dicting equations was evaluated according to ascites severity (no, moderate, or refractory) and to he

245 ion showed the best performance whatever the ascites severity and in presence of a significant renal

246 s variceal bleeding, cirrhosis etiology, and ascites severity.

247 ed jugular venous pressure and those without ascites showed directional favorability of tolvaptan ove

248 ocol use of NSBBs in cirrhosis patients with ascites shows that NSBBs did not increase mortality; the

249 c decompensation, determined by diagnoses of ascites, spontaneous bacterial peritonitis, or esophagea

250 arge diagnosis or 2 outpatient diagnoses for ascites, spontaneous bacterial peritonitis, or esophagea

251 marginally more patients with prior sepsis, ascites, steroid use, bleeding disorders, and disseminat

252 S4 ascites stimulated tumorigenesis/metastasis in vivo, and

253 in in human short-term cultures derived from ascites, such as TSPAN12, that could mediate the anti-me

254 essed genes (DEGs) associated with resistant-ascites syndrome (resistant-AS), we used innovative tech

255 oesophageal variceal bleeding and refractory ascites than sub-acute group (P < 0.001).

256 ally via the peritoneal fluid, and later via ascites that accumulates as a result of disruption of th

257 d ID8 cells form multiple tumor deposits and ascites that resemble human high-grade serous ovarian ca

258 o SAAG and/or total protein concentration in ascites, the test that best discriminated HF-related asc

259 In those with resolved ascites, the TIPS-to-PV flow ratio was 0.8 +/- 0.2 and 0

260 ficacy within the immunosuppressed malignant ascites tissue microenvironment.

261 zed 54 stable outpatients with cirrhosis and ascites to rifaximin 550 mg twice a day (n = 36) or plac

262 volume were lower in rats with cirrhosis and ascites treated with FE 204038.

263 Natural fluidic streams of malignant ascites triggered by physiological factors, including gr

264 Ascites tumor cells (ATCs) represent a potentially valua

265 univariate analysis were albumin, bilirubin, ascites, tumor size 5 cm or smaller, focality, distribut

266 tors of overall survival to be bilirubin, no ascites, tumor size 5 cm or smaller, solitary lesion, ba

267 Biodistribution study in mice with Ehrlich ascites tumors showed that (99m)Tc-DMA achieved its high

268 HCC patients pre-procedure serum bilirubin, ascites, tumour size and female gender predicted PEF pos

269 p, one of whom was admitted to hospital with ascites twice), sepsis (four patients in the G-CSF plus

270 The most common serious adverse events were ascites (two patients in the G-CSF group and two patient

271 organs of the peritoneal cavity and produce ascites, typical of ovarian cancer.

272 y mass index, liver iron deposition, massive ascites, use of 3.0 T, presence of cirrhosis, and alcoho

273 39% of the 865 patients with cirrhosis with ascites used PPIs, 52% used them at some point during th

274 reverse the vascular pathology of malignant ascites using fluid from human patients and an immunocom

275 espectively) on liver decompensation events (ascites, variceal bleeding, encephalopathy, and/or hepat

276 Yellowtail ascites virus (YAV) is an aquabirnavirus that causes asc

277 arterial pressure, cardiac output, SVR, and ascites volume were also measured after 6 days.

278 SVR was higher and cardiac output and ascites volume were lower in rats with cirrhosis and asc

279 en size, tumor cell spleen infiltration, and ascites volume, were observed in nontreated animals and

280 (M2) macrophages and dramatically decreased ascites volume.

281 rtality rate in culture negative neutrocytic ascites was 39.41% (n = 67).

282 Cirrhosis with ascites was CCl(4) induced in rats.

283 ceptor expression in rats with cirrhosis and ascites was markedly enhanced in the mesenteric circulat

284 ated HF-related ascites from other causes of ascites was serum BNP.

285 hages' role in the pathogenesis of malignant ascites, we blocked macrophage function in ID8 mice usin

286 cs closely resembling those found in vivo in ascites, we show that IRF4 and MAFB were critical regula

287 90-day mortality of cirrhotic patients with ascites were 1.81 (1.54-2.11) and 1.60 (1.43-1.80) respe

288 ltivariable regression analysis, obesity and ascites were associated with significantly increased odd

289 Tumor biopsies or malignant ascites were collected from patients before treatment (d

290 this correlation improved when patients with ascites were excluded (r = 0.82).

291 proved when patients with recent drainage of ascites were excluded.

292 Consecutive patients with new onset ascites were prospectively enrolled in this cross-sectio

293 A total of 45 patients with ascites were prospectively recruited.

294 h peritoneal tumor dissemination and massive ascites, which contribute to high mortality in ovarian c

295 ion of patients with cirrhosis and recurrent ascites who survive transplantation-free for 1 year, com

296 ram, to enroll 4,576 cirrhotic patients with ascites, who were discharged from Taiwan hospitals betwe

297 ects of NSBBs in patients with cirrhosis and ascites with and without SBP.

298 r gastrointestinal bleeding, and low-protein ascites with associated poor liver function.

299 m an indication for TIPS had been refractory ascites, with a history of OHE or of renal failure, lowe

300 ion occurring in patients with cirrhosis and ascites, with associated mortality often as high as 40%.